The paper has a title that does what good papers do — it states its own thesis: "Glycerol-driven TNAP activation in thermogenesis and mineralization." Mohammed Faiz Hussain is the first author. Lawrence Kazak — Associate Professor in the Department of Biochemistry at McGill University and Canada Research Chair in Adipocyte Biology — is the senior author. The journal is Nature. The publication week is May 12. The DOI is 10.1038/s41586-026-10396-9. [1] The companion paper, by Timothy Bromage's group at New York University on palaeometabolomes — the metabolic signatures preserved in ancient bone — appeared in the same issue and was also led by a co-author with McGill affiliation. McGill's Faculty of Dental Medicine and Oral Health Sciences pulled the two together in a single institutional announcement. [2] The paper's May 13 brief had treated the Kazak work as a Wednesday discovery story. Today, it is two peer-reviewed Nature papers from one university in one week.

The mechanism Kazak's group has cracked is satisfying in the way good biology is satisfying. Brown fat — the metabolically active tissue that mammals use to generate heat by burning calories rather than storing them — was thought, for decades, to rely on a single uncoupling pathway centred on the protein UCP1. The Kazak laboratory had previously shown, in 2021 papers in Nature and in Nature Metabolism, that brown fat also uses a parallel pathway called the futile creatine cycle — in which the enzyme creatine kinase B phosphorylates creatine to phosphocreatine, and the enzyme tissue-nonspecific alkaline phosphatase (TNAP) hydrolyses the phosphocreatine back to creatine, consuming ATP and producing heat. The cycle is "futile" in the technical sense that it produces no net chemical change but consumes energy. The two enzymes pump heat into the body by running an apparent metabolic loop. [3]

The question Kazak's new paper answers is how that pathway turns on. The mystery for four years has been: how does TNAP know to engage? The answer, it turns out, is glycerol — the three-carbon backbone released when stored fat is broken down. When the body is exposed to cold, lipase enzymes break down triglycerides in adipocytes, releasing fatty acids and glycerol. The glycerol binds, the new paper shows, to a specific pocket on the TNAP enzyme — the "glycerol pocket" — and activates its phosphocreatine-hydrolysing function. [2] In other words, the same metabolic signal that announces "the body needs heat" — the breakdown of stored fat — is also the signal that activates the alternative heat-producing pathway. The system is autonomous. It does not require an external instruction. It senses its own substrate and turns itself on.

That would have been a sufficient discovery. What makes the paper a feature rather than a finding is the second pathway it lights up. TNAP is not only a brown-fat enzyme. TNAP is also one of the body's central enzymes for bone mineralisation — the process by which calcium and phosphate are deposited in collagen matrix to harden bone. Genetic mutations that impair TNAP function cause hypophosphatasia, a rare disorder of "soft bones" that produces fractures, skeletal deformities and, in severe forms, infant mortality. Hypophosphatasia has a higher incidence in parts of Canada — notably Quebec and Manitoba — owing to inherited mutations in select founder populations. [2] McGill's Marc McKee, Professor in the Faculty of Dental Medicine and a Canada Research Chair in Biomineralization, is a co-author on the Kazak paper and has spent his career on hypophosphatasia. He helped develop, with José-Luis Millán of the Sanford Burnham Prebys Medical Discovery Institute, the first-in-class bone-targeted enzyme replacement therapy now used to treat the disorder.

The mechanistic surprise is that the glycerol pocket the Kazak group identified in brown fat appears to play a direct role in TNAP's mineralisation function as well. When the team tested hypophosphatasia-causing mutations in TNAP — mutations that disrupt the enzyme's function in bone — they found that the same mutations impaired the glycerol-pocket binding that switches on the brown-fat function. The pocket is shared. The activation logic is shared. The therapeutic implication is what McKee said in the McGill Newsroom statement: "increasing the activity of the TNAP enzyme through its glycerol pocket by natural or synthetic bioactive compounds could potentially boost the beneficial actions of the enzyme in patients, to help restore deficient bone mineralization to healthy levels." [4]

The drug-screen pipeline is funded. The Canadian Institutes of Health Research grant to Kazak and structural biologist Alba Guarné, Canada Research Chair in Macromolecular Machines in DNA Damage and Repair, runs $1.048 million over five years through 2029. [5] Guarné's structural-biology expertise is the reason the glycerol-pocket finding has the resolution it has — the paper includes crystallographic data showing exactly how glycerol fits into the TNAP active site. The drug-candidate screening that flows from a crystallographic active-site map is a different kind of drug discovery from the hopeful synthesis approach that dominates much of small-molecule pharmacology. When you can see the pocket, you can design the molecule. The CIHR funding provides the runway to do the design work.

The companion paper does something different. Bromage's group at NYU, using palaeometabolomes from ancient bone samples, traces the deep-time evolutionary record of mineralisation pathways across vertebrate lineages. The McGill Dental Faculty announcement notes that the companion paper extends the temporal frame of mineralisation biology backward across hundreds of millions of years. The two papers, taken together, frame TNAP both as a contemporary therapeutic target — for hypophosphatasia and potentially for obesity and metabolic disease — and as a pathway with deep evolutionary roots that explain why so many vertebrate species share its biology. [2]

The institutional-moment artifact this paper is holding is not the discovery alone but its company. A single Nature paper from a single laboratory is a normal achievement in a strong university. Two Nature papers in one week — one mechanistic, one evolutionary, paired in an announcement by the same faculty — is the kind of moment that signals concentrated capacity. McGill's Faculty of Dental Medicine and Oral Health Sciences is now an institutional address with two Nature papers in May 2026 to its name, both centred on TNAP and bone mineralisation.

What the paper does not yet tell us is whether the glycerol-pocket activator, once designed, will translate from mice to humans. The Kazak group's work has been almost entirely in mice — including the cold-acclimation experiments that originally identified TNAP as cold-inducible. Whether a small-molecule activator of the glycerol pocket would actually increase TNAP function in human brown fat (which exists in adults but at lower volumes than in rodents) or in human bone-mineralising cells (which behave differently from murine osteoblasts in several ways) is a question the drug-screen pipeline funded through 2029 is designed to answer. The screen is starting. The CIHR funding is committed. The Nature paper is the platform on which both the bone-disease and the metabolic-disease applications will rest.

For the lost-science thread the paper has been carrying, the McGill double is the kind of positive science counterweight the thread needs. Federal research budgets are contracting in the United States; the Canadian Institutes of Health Research grant supports five years of follow-on work in Montreal; the Nature publication record places Canadian academic biochemistry into one of the highest-visibility journals available. Capacity, when it exists, looks like this — a glycerol pocket, a five-year grant, two papers in the same week.

-- KENJI NAKAMURA, Tokyo